More on RGNX
Data
Upcoming Events
News
|
|||||
|---|---|---|---|---|---|
| Prev. Close | $8.72 |
|
|||
| Open | $8.46 | ||||
| 52 Wk High | $25.00 | ||||
| 52 Wk Low | $7.07 | ||||
| Day High | $8.69 | ||||
| Day Low | $8.31 | ||||
| P/E | N/A | ||||
| EPS | $0.00 | ||||
| Volume | 1,383,493 | ||||
- REGENXBIO Inc. Sued for Securities Law Violations – Investors Should Contact The Gross Law Firm Before April 14, 2026 to Discuss Your Rights – RGNX
- Regenxbio Inc. (RGNX) PT Lowered to $18 at Leerink Partners
- Clear Street Reiterates Buy Rating on Regenxbio Inc. (RGNX): "market is overly discounting the strength of early ‘202 data"
- Form 10-K REGENXBIO Inc. For: Dec 31
- Regenxbio Inc. (RGNX) PT Lowered to $17 at Morgan Stanley
- Regenxbio Inc. (RGNX) PT Lowered to $42 at Stifel
- Portnoy Law Firm Announces Class Action on Behalf of REGENXBIO, Inc. Investors
- Form 8-K REGENXBIO Inc. For: Mar 05
- Regenxbio (RGNX) Misses Q4 EPS by 58c
- REGENXBIO Reports Fourth Quarter and Full Year 2025 Financial Results and Operational Highlights
Entities mentioned with RGNX
- FDA | View Related Stories »
- Earnings | View Related Stories »
- Definitive Agreement | View Related Stories »
- ARK | View Related Stories »
- Maynard Um | View Related Stories »
- Mark Zuckerberg | View Related Stories »
- Morgan Stanley | View Related Stories »
- 13G | View Related Stories »
- Show More...
